Mutations in DNAH5 account for only 15% of a non-preselected cohort of patients with primary ciliary dyskinesia
- M Failly1,
- L Bartoloni1,
- A Letourneau1,
- A Munoz1,
- E Falconnet1,
- C Rossier1,
- M M de Santi2,
- F Santamaria3,
- O Sacco4,
- C D DeLozier-Blanchet1,
- R Lazor5,6,
- J-L Blouin1,7
- 1Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland
- 2Department of Human Pathology and Oncology, University of Siena, Italy
- 3Department of Pediatrics, Federico II University, Napoli, Italy
- 4UO Pneumologia IRCCS G. Caslini, Genova, Italy
- 5Department of Respiratory Medicine, University Hospital of Bern, on behalf of the Swiss Group for Interstitial and Orphan Lung Diseases (SIOLD), Bern, Switzerland
- 6Reference Center for Orphan Pulmonary Diseases, Louis Pradel University Hospital, Lyon, France
- 7Genetic Medicine, University Hospitals of Geneva, Geneva, Switzerland
- Dr J-L Blouin, Genetic Medicine and Development, University Medical Center, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland; jean-louis.blouin{at}medecine.unige.ch
- Received 19 June 2008
- Revised 3 September 2008
- Accepted 11 September 2008
Abstract
Background: Primary ciliary dyskinesia (PCD) is characterised by recurrent infections of the upper respiratory airways (nose, bronchi, and frontal sinuses) and randomisation of left–right body asymmetry. To date, PCD is mainly described with autosomal recessive inheritance and mutations have been found in five genes: the dynein arm protein subunits DNAI1, DNAH5 and DNAH11, the kinase TXNDC3, and the X-linked retinitis pigmentosa GTPase regulator RPGR.
Methods: We screened 89 unrelated individuals with PCD for mutations in the coding and splice site regions of the gene DNAH5 by denaturing high performance liquid chromatography (DHPLC) and sequencing. Patients were mainly of European origin and were recruited without any phenotypic preselection.
Results: We identified 18 novel (nonsense, splicing, small deletion and missense) and six previously described mutations. Interestingly, these DNAH5 mutations were mainly associated with outer + inner dyneins arm ultrastructural defects (50%).
Conclusion: Overall, mutations on both alleles of DNAH5 were identified in 15% of our clinically heterogeneous cohort of patients. Although genetic alterations remain to be identified in most patients, DNAH5 is to date the main PCD gene.
Footnotes
-
‣ Additional tables and figure are published online only at http://jmg.bmj.com/content/vol46/issue4
-
Funding: This work was supported by grants from the Swiss National Science Foundation (#3200BO-105838, to JLB), the Carvajal ProKartagener Foundation (to JLB), and the Société Académique de Genève on behalf of Fonds Dr E Rapin (to MF and JLB). LB was supported by a Marie Heim-Vögtlin grant from Swiss National Science Foundation. The Swiss Group for Interstitial and Orphan Lung Diseases was supported by the Swiss Academy of Medical Sciences, the Swiss Respiratory Society, the Swiss Pulmonary League, the Geneva Pulmonary League, Geneva University Hospitals, Bern University Hospital, the Carvajal ProKartagener Foundation, GlaxoSmithKline, Actelion and Aventis.
-
Competing interests: None declared.
-
Patient consent: Obtained.
